Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

[68Ga]Ga-FAPI total body PET/CT for improving diagnostic sensitivity and preoperative staging in gastroesophageal cancer and pancreatic canc… Ended

2023-503632-41-01 Pancreatic cancer and gastroesophageal cancer (esophagu 4 2024-01-30
Pembro-CORE pilot Ended

2022-501306-35-00 First relapse or primary refractory of classical Hodgki 4 2024-01-26
A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended

2023-503288-40-00 Unresectable or Metastatic Melanoma 5 2024-01-26
A study of zipalertinib and chemotherapy compared with chemotherapy alone in patients with advanced Non-Small Cell Lung Cancer with Epiderma… Ended

2023-503575-21-00 Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Inser 5 2024-01-23
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Neoplasms, Head and Neck 4 2024-01-19
DAREONTM-9: A study to test how well different doses of BI 764532 are tolerated by people with small cell lung cancer when taken together w… Ended

2023-506007-26-00 relapsed/refractory extensive stage - small cell lung c 3 2024-01-15
DAREON™-7: A study to test how well different doses of BI 764532 in addition to chemotherapy are tolerated by people with advanced neuroendo… Ended

2023-505870-13-00 Extra-pulmonary neuroendocrine carcinoma (epNEC) 3 2024-01-11
DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small… Ended

2023-506008-20-00 Extensive-stage small cell lung carcinoma (ES-SCLC) 3 2024-01-11
A randomized, open-label, multi-center phase III trial comparing tisagenlecleucel to standard of care in adult participants with relapsed or… Ended

2023-503452-27-00 Adult patients with follicular B-cell non-Hodgkin lymph 5 2024-01-02
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended

2022-502231-19-00 ER+/HER2- Advanced or Metastatic Breast Cancer 9 2024-01-02
TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of Vepdegestrant (ARV-471) in Combination With Other Medicines… Ended

2022-502228-34-00 ER +/HER2- Advanced or Metastatic Breast Cancer 9 2023-12-27
ETOP 14-18 CHESS: Immunotherapy, chemotherapy and radiotherapy, followed by surgery or radiotherapy, for patients with newly diagnosed non-s… Ended

2024-511134-12-00 NSCLC, synchronous oligo-metastatic 4 2023-12-20
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended

2022-502669-14-00 Small cell lung cancer (SCLC) 5 2023-12-18
Study of safety, tolerability and efficacy of DFV890 in adult participants with myeloid diseases Ended

2022-501406-36-00 Myeloid disease 3 2023-12-14
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Metastatic leiomyosarcoma 5 2023-12-12
Phase I study evaluating the safety and efficacy of MEDI5752 in combination with stereotactic radiotherapy in patients with metastatic sarco… Ended

2024-515551-38-00 Metastatic soft tissue sarcoma 3 2023-12-12
A Study to Learn How Linvoseltamab (REGN5458) Will Work Compared to the Elotuzumab, Pomalidimide and Dexamethasone (EPd) Combination, in Par… Ended

2022-501396-62-00 Relapsed Refractory Multiple Myeloma 5 2023-12-12
A Phase 2, open-label, multi-centre, multi-national interventional trial to evaluate the efficacy and safety of erdafitinib (ERDA) monothera… Ended

2024-512573-27-01 Muscle-invasive bladder cancer (MIBC) 4 2023-12-11
CA-4948-104: A Ph1 Study of Emavusertib in AML CR MRD+ Patients Currently Receiving Azacitidine and Venetoclax Ended

2023-505828-58-00 Acute Myeloid Leukemia 3 2023-12-05
A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patients Ended

2023-505160-12-00 Essential Thrombocythaemia 5 2023-12-04
Subcutaneous immunoglobulin (HyQvia) against early infections in multiple myeloma: SHIELD Ended

2023-505053-40-00 Multiple Myeloma 4 2023-11-30
Diagnostic Accuracy Study for OWL-EVO1 as a Lung Cancer EVOC® Probe Ended

2023-503574-20-00 Lung Cancer 4 2023-11-29
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination with Pembrolizumab, TransCon TLR7/8 Agonist, or … Ended

2023-509143-27-00 Locally advanced or metastatic solid tumor malignancies 7 2023-11-27
Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended

2023-503265-27-00 Participants with Untreated T4N0 or Stage III dMMR/MSI- 5 2023-11-23